Lipum Q4 report: Clinical progress and a SEK187m rights issue - Redeye

Redeye provides a research update on Lipum following the Q4 report published by the company earlier today. Bolstered by the recent positive interim results from the ongoing phase I study with lead candidate SOL-116, Lipum announces that it is strengthening its finances through a SEK187m rights issue and is advancing the candidate into phase II trials.

Länk till analysen i sin helhet: https://www.redeye.se/research/986869/lipum-q4-report-clinical-progress-and-a-sek187m-rights-issue?utm_source=finwire&utm_medium=RSS